Curis (CRIS)
(Delayed Data from NSDQ)
$6.32 USD
+0.15 (2.43%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $6.31 -0.01 (-0.16%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.32 USD
+0.15 (2.43%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $6.31 -0.01 (-0.16%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Zacks News
What Makes Curis (CRIS) a New Buy Stock
by Zacks Equity Research
Curis (CRIS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Strength Seen in Curis (CRIS): Can Its 19.5% Jump Turn into More Strength?
by Zacks Equity Research
Curis (CRIS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
2seventy bio, Inc. (TSVT) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
2seventy bio, Inc. (TSVT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pharming Group N.V. Sponsored ADR (PHAR) Soars 14.7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Pharming Group N.V. Sponsored ADR (PHAR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Curis (CRIS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Curis (CRIS) delivered earnings and revenue surprises of 0% and 14.35%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Curis (CRIS) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Curis (CRIS) delivered earnings and revenue surprises of -9.09% and 7.57%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 0% and 5.10%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Curis (CRIS) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Curis (CRIS) delivered earnings and revenue surprises of 14.29% and 4.72%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Editas (EDIT) delivered earnings and revenue surprises of -4.76% and 43.33%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Curis (CRIS) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Curis (CRIS) delivered earnings and revenue surprises of 17.65% and 6.77%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Agenus (AGEN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agenus (AGEN) delivered earnings and revenue surprises of -5.56% and 14.69%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Curis (CRIS) Gets FDA Nod to Partly Resume Leukemia Study
by Zacks Equity Research
The FDA allows Curis (CRIS) to resume enrollment of additional patients in the monotherapy phase of the TakeAim Leukemia study on emavusertib in patients will acute myeloid leukemia and myelodysplastic syndrome. Shares down.
Curis (CRIS) Lymphoma Study's Clinical Hold Lifted, Shares Gain
by Zacks Equity Research
The FDA lifts partial clinical hold on Curis' (CRIS) phase I/II TakeAim lymphoma study investigating emavusertib in patients with B-cell malignancies. Shares surge.
Curis (CRIS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Curis (CRIS) delivered earnings and revenue surprises of 0% and 1.40%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Curis (CRIS) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Curis (CRIS) delivered earnings and revenue surprises of -5.88% and 6.71%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Down 31.3% in 4 Weeks, Here's Why You Should You Buy the Dip in Curis (CRIS)
by Zacks Equity Research
Curis (CRIS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Voyager Therapeutics (VYGR) Moves 5.8% Higher: Will This Strength Last?
by Zacks Equity Research
Voyager Therapeutics (VYGR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Curis (CRIS) Down on FDA Partial Clinical Hold on Lymphoma Study
by Zacks Equity Research
The FDA places a partial clinical hold on Curis' (CRIS) phase I/II TakeAim lymphoma study investigating emavusertib in patients with B-cell malignancies. Shares fall.
Curis (CRIS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Curis (CRIS) delivered earnings and revenue surprises of -15.38% and 3.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exact Sciences (EXAS) delivered earnings and revenue surprises of -40.66% and 0.15%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Is the Options Market Predicting a Spike in Curis (CRIS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Curis (CRIS) stock based on the movements in the options market lately.
Curis (CRIS) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Curis (CRIS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is the Options Market Predicting a Spike in Curis (CRIS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Curis (CRIS) stock based on the movements in the options market lately.
Here's Why Curis (CRIS) Could be Great Choice for a Bottom Fisher
by Zacks Equity Research
Curis (CRIS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Down 23.2% in 4 Weeks, Here's Why Curis (CRIS) Looks Ripe for a Turnaround
by Zacks Equity Research
Curis (CRIS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.